About MetrioPharm AGMetrioPharm AG is a biotech company developing oral drug compounds for the treatment of autoimmune and other inflammatory diseases. MetrioPharm’s MP1000 pipeline consists of small molecule immune modulators for unmet medical needs in Immune-Mediated Inflammatory Diseases (IMIDs).
Founder and CEO: Wolfgang Brysch
Founder and COO: Ekkehard Brysch
CFO: Holger Dunker
Please click here for clinical trial information.
5 articles with MetrioPharm AG
MetrioPharm AG, a pharmaceutical company developing drugs for chronic inflammatory diseases, is expanding its management team.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
MetrioPharm AG: MetrioPharm AG Phase II Data in Psoriasis Show Dose-Response, Disease Modifying Activity and Outstanding Safety Profile
MetrioPharm AG, a clinical stage biopharmaceutical company, reports positive results from its recently completed Phase II dose finding study of MP1032 in psoriasis patients.
MetrioPharm AG, a pharmaceutical development company, welcomes Sven Zimmermann, as its new Chief Financial Officer, bringing more than a decade of experience in strategic transactions.
MetrioPharm AG Announces Positive Top-Line Results From A Phase IIa Study In Moderate-To-Severe Psoriasis With Its Oral Lead Compound MP1032